Starpharma launches Viraleze in the UK

Pharmaceutical developer Starpharma has secured United Kingdom distribution for its Viraleze antiviral nasal spray. The Melbourne company has signed a sales and distribution agreement with LloydsPharmacy which operates 1,400 pharmacy stores in the UK and is part of international pharma distributor group McKesson. McKesson supplies more than 14,000 pharmacies across the UK. Viraleze spray, which…

Manufacturing news briefs — stories you might have missed

Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…

Manufacturing news briefs – stories you might have missed

Imagion completes move to new R&D, production facility Breast cancer detection company Imagion Biosystems has moved into new facilities housing its offices, R&D activities and nanoparticle synthesis operation. The facility provides additional manufacturing capacity for its specialised MagSense nanoparticles. These are coated with tumour targeting antibodies which are used to test for HER2 positive breast…

Starpharma’s Covid-killer needs action not bureaucracy from TGA

By Peter Roberts I have nothing but the deepest respect for Australia’s Therapeutic Goods Administration, but a certain lack of initiative on the part of the TGA seems to be preventing Australians from getting access to the latest Australian-developed tools to fight Covid-19. Make no mistake the TGA has an exemplary record in regulating Australians’…